Related Experiment Video
Updated: Jul 13, 2026

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
Aromatase inhibitors and bone
1The Academic Unit of Bone Metabolism, Musculoskeletal Section, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK. r.eastell@sheffield.ac.uk
Abstract:
The decrease in estrogen levels with the use of aromatase inhibitors results in an increase in the rate of bone remodelling. This result in an acceleration of bone loss, and probably to an increase in the risk of fractures. The risk of fracture is particularly high in the older woman and in the woman with a low bone mineral density. We have a number of proven treatments for the treatment of postmenopausal osteoporosis and it is likely that some of these, particularly bisphosphonates, could be effective at preventing bone loss with aromatase inhibitors.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Oral Hypoglycemic Agents: Biguanides and Glitazones
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Lipid-Lowering Drugs: Statins and Miscellaneous Agents